Patient-derived organoids (PDOs) have recently emerged as robust preclinical models;
however, their potential to predict clinical outcomes in patients has remained unclear. We report …

Sequential profiling of plasma cell-free DNA (cfDNA) holds immense promise for early detection
of patient progression. However, how to exploit the predictive power of cfDNA as a liquid …

Despite biomarker stratification, the anti-EGFR antibody cetuximab is only effective against
a subgroup of colorectal cancers (CRCs). This genomic and transcriptomic analysis of the …

Background: Limited data exist regarding the correlation between MRI tumour regression
grade (mrTRG) and pathological TRG (pTRG) in rectal cancer. Methods: mrTRG and pTRG …

Background & Aims Cholangiocarcinomas (CCA) are resistant to chemotherapy, so new
therapeutic agents are needed. We performed a screen to identify small-molecule compounds …

Purpose: Response to preoperative chemo-radiotherapy (CRT) varies. We assessed
whether circulating tumor DNA (ctDNA) might be an early indicator of tumor response or …

Background Outcomes with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone)
or CHOP-like chemotherapy in peripheral T-cell lymphoma are poor. We investigated …

Objective Regorafenib demonstrated efficacy in patients with metastatic colorectal cancer (mCRC).
Lack of predictive biomarkers, potential toxicities and cost-effectiveness concerns …

There are limited data on circulating, cell-free, tumour (ct)DNA analysis in locally advanced
rectal cancer (LARC). Digital droplet (dd)PCR was used to investigate KRAS/BRAF …

Previously, we classified colorectal cancers (CRCs) into five CRCAssigner (CRCA) subtypes
with different prognoses and potential treatment responses, later consolidated into four …